When Florida father Ryan Goepel developed persistent knee pain during a trip in 2024, he assumed it was another flare of gout.
He had experienced gout before, and joint pain seemed like a familiar problem. But when the discomfort refused to disappear, his doctor ordered blood tests.
Two days later, she called with an alarming message: stop what you are doing and go directly to the hospital.
The tests had uncovered something far more serious than gout.
Goepel, then 49, was diagnosed with acute myeloid leukemia, or AML, an aggressive cancer of the blood and bone marrow. His condition deteriorated so rapidly that doctors reportedly discussed hospice with his family.
What followed was an unusual treatment journey involving a clinical trial, rapid remission and an allogeneic stem-cell transplant.
Around two years later, follow-up testing reportedly shows no detectable leukemia.
His case is striking, but the medical story behind it is even more important: the treatment strategy used in Goepel’s trial challenges the long-standing assumption that younger, medically fit patients with high-risk AML should automatically receive intensive chemotherapy first.
Table of Contents
Knee Pain Led to a Life-Changing Blood Test
Goepel was traveling in September 2024 when his knee began hurting.
Because he had gout, an inflammatory condition caused by uric acid crystals accumulating in joints, he initially assumed that was responsible.
But the pain persisted.
After returning home, he sought medical care and had blood drawn.
According to the original CBS News report on Goepel’s case, the results were concerning enough that his physician instructed him to go immediately to the hospital.
Further investigation eventually revealed AML.
The knee pain itself was not a typical diagnostic sign of leukemia. Instead, it was the symptom that led him to seek medical attention and ultimately triggered the blood testing that exposed the disease.
What Is Acute Myeloid Leukemia?
Acute myeloid leukemia is a rapidly progressing cancer involving blood-forming cells in the bone marrow.
In AML, immature abnormal myeloid cells multiply uncontrollably.
These leukemia cells interfere with the production of normal:
- red blood cells;
- platelets;
- infection-fighting white blood cells.
Because normal blood formation is disrupted, patients may develop symptoms including:
- severe fatigue;
- weakness;
- frequent infections;
- fever;
- unexplained bruising;
- bleeding;
- shortness of breath.
Bone or joint pain can occur, but it is far less specific than the abnormalities seen in blood counts.
AML can progress quickly and often requires treatment soon after diagnosis.
His Leukemia Was Classified as High Risk
After Goepel was transferred to Sylvester Comprehensive Cancer Center at the University of Miami, further testing classified his leukemia as an unfavorable or adverse-risk form of AML.
That distinction matters.
AML is not one single disease.
Genetic and chromosomal changes divide patients into biological groups with very different expected responses to treatment.
Some AML subtypes respond relatively well to conventional chemotherapy.
Others are more difficult to control and carry a greater risk of relapse.
For many younger people with intermediate- or adverse-risk AML, doctors aim to achieve remission and then proceed to an allogeneic hematopoietic stem-cell transplant, which can offer a chance of long-term disease control or cure.
A Clinical Trial Offered a Different First Treatment
Goepel enrolled in a clinical trial investigating two medicines:
venetoclax and azacitidine.
This combination was already widely used for newly diagnosed AML patients who were considered too old or medically frail for traditional intensive chemotherapy.
The new study asked a different question.
Could the same combination work as initial therapy for younger patients with non-favorable-risk AML, even when those patients were medically fit enough to tolerate intensive chemotherapy?
The answer from the small pilot trial was encouraging.
The study published in Haematologica included 36 patients aged 60 or younger with newly diagnosed intermediate- or adverse-risk AML.
The median participant age was 49.
Nearly 7 in 10 Patients Responded
Among the 36 patients treated with venetoclax plus azacitidine:
| Outcome | Trial result |
|---|---|
| Overall response rate | 69% |
| Complete remission | 53% |
| MRD-negative among responders | 68% |
| Proceeded to stem-cell transplant | 53% |
| Median follow-up | 2.9 years |
Twenty-five of the 36 patients responded to treatment.
Nineteen achieved complete remission.
Among patients who responded, 68% became measurable residual disease negative, meaning highly sensitive tests could no longer detect leukemia at the level measured.
Nineteen patients subsequently proceeded to allogeneic stem-cell transplantation.
Goepel Entered Remission Quickly
According to the patient report, Goepel entered remission shortly after beginning therapy.
That rapid response created an opportunity to move toward stem-cell transplantation.
But remission and cure are not the same thing.
In AML, complete remission generally means that standard testing no longer shows clear leukemia and blood-cell production has recovered sufficiently.
Small numbers of leukemia cells can sometimes survive.
That is why patients with high-risk disease may receive additional treatment after remission.
His Stem-Cell Transplant Was a Critical Part of the Story
Goepel later received an allogeneic stem-cell transplant.
This step is essential when interpreting his long-term outcome.
It would be inaccurate to claim that venetoclax plus azacitidine alone “cured” his AML.
His treatment sequence was closer to:
venetoclax + azacitidine → remission → stem-cell transplant → continued monitoring
The drug combination helped bring the disease under control.
The transplant then served as consolidation therapy with curative intent.
In the trial overall, more than half of participants successfully reached transplantation after venetoclax and azacitidine.
What Does ‘Cancer-Free’ Mean in AML?
Popular reports describe Goepel as cancer-free.
Medically, more precise terms are preferable.
For leukemia, doctors may describe patients as:
- in complete remission;
- MRD-negative;
- having no detectable disease.
Even after years of remission, AML can sometimes return.
That is why long-term follow-up remains necessary after treatment and transplantation.
For Goepel, the most accurate wording is that he has reportedly remained free of detectable leukemia for approximately two years.
That remains an excellent outcome.
It is simply more precise than implying that recurrence has become impossible.
The Trial Compared Patients With Historical Intensive-Chemotherapy Controls
Researchers also compared the 36 trial participants with 36 matched historical patients who had received conventional intensive chemotherapy.
The results favored the venetoclax-azacitidine group on several measures.
Overall response rates were:
- 69% with venetoclax plus azacitidine;
- 44% with intensive chemotherapy.
Stem-cell transplant in first remission occurred in:
- 53% of trial patients;
- 28% of matched controls.
Trial patients also spent substantially fewer days in hospital during the first 30 days.
The median was:
- 9 days with venetoclax plus azacitidine;
- 30 days with intensive chemotherapy.
They also required fewer blood transfusions and experienced fewer infectious complications.
Fewer Infections Were Reported
Infectious complications during the first 30 days occurred in:
- 43% of patients receiving venetoclax plus azacitidine;
- 94% of historical intensive-chemotherapy controls.
This difference is potentially important because serious infections during AML treatment can delay recovery and make it harder for patients to proceed to transplantation.
However, these comparisons require caution.
The study did not randomly assign patients to the two treatments.
The control group came from historical records.
Differences in supportive care, treatment era and clinical practice could therefore influence the results.
This Was a Small Pilot Study
The trial enrolled just 36 patients.
That is not enough to establish a new universal standard of care for younger adults with AML.
The researchers themselves emphasize that the study was small and non-randomized.
A prospective randomized trial would be needed to determine whether venetoclax plus azacitidine should routinely replace intensive chemotherapy in younger patients with non-favorable-risk disease.
The findings are best interpreted as evidence that the strategy is promising enough to justify further investigation.
The Treatment Was Not Risk-Free
Although the regimen was less intensive than conventional induction chemotherapy, it still caused serious side effects.
Grade 3 or higher complications included:
- thrombocytopenia in 53%;
- neutropenia in 42%;
- febrile neutropenia in 36%;
- anemia in 33%.
There were also serious cases of:
- mucositis;
- hypoxia;
- respiratory failure.
Two of the 36 participants died within the first 30 days.
So describing this as a gentle or harmless treatment would be misleading.
AML therapy remains medically demanding even when traditional intensive chemotherapy is avoided.
How Venetoclax Works
Venetoclax is a targeted cancer medicine that inhibits a protein called BCL-2.
BCL-2 helps certain leukemia cells avoid apoptosis, the biological process through which damaged or abnormal cells are programmed to die.
By blocking BCL-2, venetoclax makes leukemia cells more vulnerable to cell death.
Azacitidine works differently.
It is a hypomethylating agent that changes patterns of DNA methylation and gene regulation inside abnormal blood-forming cells.
When used together, the drugs can create strong anti-leukemia activity.
Why Younger Patients Usually Receive Intensive Chemotherapy
Historically, treatment decisions for AML have depended heavily on whether a person is considered medically fit enough to tolerate intensive induction chemotherapy.
Younger patients are generally more likely to receive intensive regimens because they can often withstand the toxicity better than older adults.
But the authors of the new study argue that physical fitness may not always be the best way to choose treatment.
A patient may be physically capable of surviving intensive chemotherapy while having leukemia biology that makes the disease less likely to respond to it.
That leads to a broader idea:
AML treatment may increasingly need to be selected according to the biology of the leukemia, not simply the age and physical fitness of the patient.
Some Patients Did Not Respond
The trial results were promising, but far from universal.
Eleven of the 36 patients were refractory to initial venetoclax-azacitidine therapy.
Most of those patients subsequently received intensive chemotherapy as salvage treatment.
Seven of nine evaluable patients treated with salvage intensive chemotherapy responded.
This is potentially important because it suggests that trying venetoclax and azacitidine first did not necessarily eliminate the option of later intensive chemotherapy.
But larger studies are needed to confirm that strategy.
Some Responders Relapsed Before Transplant
Five patients who initially responded subsequently relapsed before undergoing stem-cell transplantation.
That demonstrates why AML remission can be fragile, particularly in biologically high-risk disease.
The trial was specifically designed to move eligible patients toward transplantation relatively quickly after remission.
The ultimate goal was not merely to create an initial response but to use that response as a bridge to potentially curative therapy.
Why Goepel’s Case Matters
Goepel’s story is remarkable because of the contrast between the seriousness of his initial condition and his later outcome.
At one point, his family was reportedly asked to consider hospice.
He then entered an investigational treatment strategy, achieved remission and proceeded to transplantation.
Two years later, there is reportedly no detectable leukemia.
But the broader scientific significance lies beyond one patient.
His experience occurred within a clinical trial suggesting that some younger patients with unfavorable AML might potentially reach deep remission and transplantation without beginning with conventional intensive chemotherapy.
Knee Pain Should Not Be Treated as an AML Warning Sign by Itself
The unusual beginning of Goepel’s story makes knee pain an attractive headline element.
But it should not become medical advice.
Most knee pain is caused by conditions far more common than leukemia.
AML more often produces symptoms related to abnormal blood-cell production, including persistent fatigue, recurrent infection, unexplained bruising or bleeding.
The important lesson from Goepel’s case is not that knee pain means leukemia.
It is that persistent or unexplained symptoms sometimes warrant medical assessment, particularly when they do not behave like a person’s usual condition.
What the Research Really Shows
Goepel’s recovery is an individual outcome, not proof that venetoclax and azacitidine can cure every younger person with high-risk AML.
The scientific findings are nevertheless encouraging.
In a small group of younger patients with predominantly adverse-risk AML, venetoclax plus azacitidine produced a 69% response rate, deep remissions in many responders and enabled more than half of the participants to proceed to stem-cell transplantation.
Compared with historical intensive-chemotherapy controls, patients also experienced fewer hospital days, fewer transfusions and fewer infectious complications.
The next question is whether larger randomized trials can reproduce those advantages.
For now, Goepel’s story illustrates what precision treatment in leukemia increasingly aims to achieve: choosing therapy according to the biology of the cancer, reaching remission quickly and creating the safest possible path toward treatment with curative intent.
